NDAORALFOR SUSPENSION, EXTENDED RELEASE
Approved
Aug 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MICRO-K LS (potassium chloride) by Ascentage Pharma is clinical pharmacology the potassium ion is the principal intracellular cation of most body tissues. First approved in 1988.
Drug data last refreshed 1h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MICRO-K LS is an oral, extended-release potassium chloride suspension used to treat hypokalemia (low potassium levels). The drug replaces depleted potassium ions, which are essential for nerve impulse transmission, muscle contraction, and cardiac function. Potassium depletion commonly occurs in patients on chronic diuretic therapy, those with severe diarrhea, or those with diabetic ketoacidosis.
LOE Approaching
This product is in a mature, commoditized market with approaching loss of exclusivity, suggesting limited expansion opportunities and potential team consolidation.
Mechanism of Action
CLINICAL PHARMACOLOGY The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac,…
Worked on MICRO-K LS at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.